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Objective. To investigate the independent and additive eﬀects of resistance training (RT) and soy isoﬂavone (ISO) on body
composition in postmenopausal women (PW). Method. This study used a placebo-controlled, double-blind (soy), randomized
(ISO versus placebo)×(RT versus No RT) design. A total of 80PW, aged 45–70 years, were randomly (71 completed 9-months
intervention): RT + ISO (n = 15), No RT + ISO (n = 20), RT + placebo (n = 18), and No RT + placebo (n = 18). ISO received
100mg a day of isoﬂavone; and to RT attended supervised resistance training sessions. At baseline and 9-months, fat and muscle
mass were estimated by DXA. ANOVA and test t were used. Results. RT groups showed signiﬁcantly increased muscle strength
(35.2%) and muscle mass (1.4%). Exercising attenuated gains in fat trunk and % body fat (P<. 05). Signiﬁcant decreases in
muscle mass (−1.8%) and increases in fat mass of the whole-body (1.6%) and trunk (9.7%) was found in no-RT groups (P<. 05).
InISOgroups,therewerenodiﬀerencesinbodycompositionandmusclestrength.ISOandRThadnoadditiveeﬀects.Conclusion.
In PW: RT improved muscle mass and strength and attenuated gain of fat mass; ISO did not alter body composition and muscle
strength; there were no additive eﬀects of RT and ISO.
1.Introduction
Ad e c r e a s ei ne s t r o g e np r o d u c t i o ni nw o m e na tm e n o p a u s e
is accompanied by changes in body composition which
are characterized by body fat increase, primarily at the
abdomen, and progressive reduction in muscle mass (sar-
copenia)[1].Sarcopeniaisusuallyassociatedwithfunctional
impairment and physical disability, especially in women,
and is the direct cause of reduction in muscle strength
[2–4]. Menopause may induce a phase of rapid decreases
in aerobic ﬁtness, muscle strength, and balance, especially
in sedentary women [5]. Several factors such as diet,
lifestyle, as well as metabolic and hormonal parameters
inﬂuence body composition in postmenopausal women
[1, 6, 7].
The importance of physical activity at all stages of life
for optimal bone health and muscle mass is established
[8]. Aerobic exercise is important in maintaining overall
health. Nonetheless, resistance muscle training may be
more applicable to site-speciﬁc eﬀects of exercise, besides
having more favorable eﬀects on maintaining or improving
muscle mass and strength. Recently, we studied the eﬀect
of 16 weeks of resistance training (60%–80% of one-
repetition maximum—1-RM) three times a week in 43
postmenopausal women, and we observed increases in
maximalstrengthandmusclemass,indicatingthatresistance
training may be applied in the rehabilitation or prevention
of sarcopenia in postmenopausal women [9]. Besides, the
abdominalfatreductionisassociatedwithresistancetraining
in older women [10, 11].2 Obstetrics and Gynecology International
Isoﬂavonesbelongtoaclassofcompoundscalledphytoe-
strogens. The primary isoﬂavones found in soy are genistein,
daidzein, and glycitein. These nonsteroidal compounds are
structurally [12] and weakly bound to estrogenic receptors
[13]. Isoﬂavones may have a direct eﬀect on muscle via
estrogen receptors [14], increase of blood concentration of
insulin-like growth factor-1 [15], or through their eﬀects
on reducing inﬂammation [16]. Besides, estrogen receptors
are present in adipose tissue [12]. Thus, isoﬂavones could
participate in the regulation of adiposity [12, 17].
However, the details of combined eﬀects of regular
resistance exercise and isoﬂavone on the prevention muscle
loss or fat gain in women estrogen deﬁcient remain to be
solved. We observed that 16 weeks of supplementation with
soy protein associated with resistance training did not result
ingreaterincreaseinstrengthormusclemasscomparedwith
placebo in postmenopausal women [10]. In this study, the
time of intervention of the isoﬂavone could have aﬀected
the results. Two studies demonstrated association between
muscle mass and isoﬂavone; however, the postmenopausal
w o m e nr e c e i v e di s o ﬂ a v o n ef o r2 4w e e k s[ 18, 19].
Therefore, clinical trials of longer duration are needed
to determine the eﬀect of exercise training combined with
isoﬂavoneonbodycomposition.Withinthiscontext,thepri-
mary purpose of this study was to determine the isolated and
combined eﬀects of resistance training and soy isoﬂavone on
body composition (fat and muscle mass) in postmenopausal
women.
2. Methods
2.1. Study Design and Participants. This clinical randomized,
double-blind, placebo-controlled trial included 80 Brazilian
women seen at the Climacterium Outpatient Service of the
Department of Gynecology of Sao Paulo State University. All
subjects were postmenopausal women aged 45–70 years with
good overall health, sedentary, spontaneous amenorrhea for
at least 12 months, and follicle-stimulating hormone level
greater than 40mIU/mL. Exclusion criteria included (1)
high-ﬁber or high-soy diet, (2) hormone therapy (HT) or
phytoestrogens use within the preceding 6 months, (3) non-
controlled high-blood pressure, (4) history of myopathic,
neuropathic, and skeletal disorders, (5) history of breast
cancer, endometrial carcinoma, cardiovascular disease, and
thromboembolic disorders, (6) undiagnosed vaginal bleed-
ing, (7) alcoholism, and (8) chronic gastrointestinal diseases.
Subjects were considered to be sedentary when they reported
no leisure physical activities besides everyday household
tasks. Informed consent was obtained from all participants,
and the study was approved by the Research Ethics Commit-
tee of Botucatu Medical School, UNESP.
Initialassessmentconsistedofcasehistorytaking,general
and gynecological physical examination, oncotic colpocy-
tology, mammography, and transvaginal ultrasonography.
Data collected included information on age, menarche,
time since menopause, parity, HT contraindication, weight,
height, and waist circumference. After a prestudy period,
participants were randomly assigned to one of two groups:
ISO, receiving soy isoﬂavone extract (n = 40) or P, receiving
placebo (n = 40). Examiners and subjects had no previous
knowledge of group assignment (double-blind). Placebo
and active treatment were identical in appearance. The
centralized computerized subject randomization process was
conducted by a statistician unaware of the study protocol
using speciﬁc software. Capsule packages were labeled with
code numbers and the statistician in charge was the only
unblinded person.
Thus, 40 participants were given 250mg of standardized
soy extract (Glycine max), corresponding to 100mg/day of
isoﬂavone, twice a day in capsules containing 125mg of soy
extract plus 50mg of isoﬂavones each, in glycoside form.
The standardized extract contained approximately 50% of
genistein and 35% of daidzein. The other 40 participants
received two lactose capsules per day. All of the capsules
were identical in appearance. Subjects were instructed to
return any unused medication during visits for compliance
determination.
Subsequently, the participants were randomized to resis-
tance training (RT) or No RT. Thus, 80 women were
randomly assigned to one of four groups: RT + ISO (n =
20), No RT + ISO (n = 20), RT + P (n = 20), and No RT +
P( n = 20). Followup length was nine months and
evaluations were performed during the prestudy period, at
baseline and at the end of the study. Nine women withdrew
from the study (7 in RT and 2 in No RT) because of
illness, family problems, or protocol violation (less than 2
weekly RT sessions). The remaining 71 subjects completed
the nine-month study, and their data were included in the
per-protocol analysis.
All participants realized alimentary register. Three-day
diaries (2 weekdays and 1 weekend day) and 24-hour recalls
were completed at baseline of the study to estimate caloric
intake and diet composition. Total energy, macronutrients
(proteins, fats, and carbohydrates), and calcium contents
were determined using “NutWin” (nutrition analysis soft-
ware). Participants were advised to keep their usual dietary
habits. The participants that showed inadequate data were
oriented for ideal.
2.2. Exercise Intervention. The resistance-training protocol,
as adapted for women over 45 years, consisted in the
minimum 2 weekly sessions, on nonconsecutive days, for 9
months, under the supervision of trained personnel. Before
training, subjects in the exercise group attended a 4-week
adaptation period in order to get acquainted with the proto-
col. Initially, lighter loads were used and subjects performed
one set of 15 repetitions at 40%–50% of 1-RM. Progression
wasgradualuntill3setsof8–12repetitionsat60%–80%of1-
RM were performed [20]. The protocol consisted of dynamic
exercises for both lower and upper limbs for a total of 50–60
minutes. Two exercises for each major muscle group (chest,
back, and thigh) and one for each minor muscle group
(bicepsandtriceps)wereused,in3seriesof8–12repetitions.
The load setting for each individual exercise was established
by 1-RM testing. Loads were periodically adjusted at the
end of each month to maintain loads at 8–12 repetitions
maximum, according to strength gain and adaptation to
training. Subjects performed one set of each of the followingObstetrics and Gynecology International 3
exercises: leg press, leg extension, peck deck, bench press,
seated row, lat pull-down, triceps pulley, and biceps curl.
Abdominal (3 sets of 30 repetitions) and calf exercises (3
sets of 20 repetitions with body weight) were also included.
Air breathing was controlled by expiring during concentric
actions and inspiring over eccentric actions in order to
prevent apnea. Rest breaks between series and exercises
ranged from 1minute and 30 seconds to 2minutes. During
training sessions, participants were advised to perform an
eccentric action in 2 second and a concentric action in
1 second. Subjects were considered as trained if they had
worked out at least two times a week, on nonconsecutive
days. Attendance was recorded by the trainers. Participants
of the no-RT groups were asked to maintain their usual
level of physical activity. No cardiovascular training was
mentioned.
Muscle strength was assessed in all subjects, by the 1-
RM test, for dynamic exercises, after an adaptation period
for strength testing (3–5 sessions on nonconsecutive days).
The 1-RM was deﬁned as the maximal weight that could
be lifted with proper body alignment and the correct
lifting technique. Muscle strength assessment included all
of exercises at baseline, but only leg extension after nine
months; because of cultural aspects related to strength, some
women did not accomplish other tests. The 1-RM test was
performed using the same apparatus used for resistance
training.
2.3. Body Composition. Weight variation was assessed by
the body mass index (BMI = weight/height
2). Height and
weight were obtained using a stadiometer (Seca, Brazil) and
a standard balance beam scale (Filizola, Brazil), respectively,
with subjects wearing lightweight clothing and no shoes.
Weight was classiﬁed according to the system used by the
World Health Organization (2000): 18.5 to 24.9kg/m2 =
normal weight, 25 to 29.9kg/m2 = overweight, and
≥30.0kg/m2 = obese [21]. Waist circumference was mea-
sured to the nearest 0.5cm midway between the lowest rib
margin and the iliac crest in supine position. Abdominal fat
was indirectly assessed by measuring waist circumference,
and was considered high when waist was >88cm.
Body composition (fat and lean mass) was assessed by
dual-energy X-ray absorptiometry (DXA) at baseline and
at nine months using a Hologic QDR-2000 densitometer
plus scanner (Hologic, Waltham, MA, USA). To minimize
interobserver variation, all scans and tests were carried out
by the same investigator. Day-to-day percent coeﬃcient of
variations was <1.0% for whole-body. Whole body scans
were divided into several regions such as arms, legs, trunk
(pelvis, spine, and ribs), and head. Body composition was
assessed by using the manual DXA analysis software (version
5.73A for whole body). The arm region was deﬁned as the
region extending from the head of the humerus to the distal
tip of the ﬁngers. The reference point between the head of
the humerus and the scapula was positioned at the glenoid
fossa. The leg region was deﬁned as the region extending
from the inferior border of the ischial tuberosity to the distal
tipofthetoes.Thesub-whole-bodywasdeﬁnedastheregion
extending from the shoulders to the distal tip of the toes.
Reference points that could be clearly visualized on the DXA
system terminal were selected.
2.4. Statistical Analysis. Statistical analyses were performed
using the Software STATISTICA for Windows (version 6.0).
The statistical distribution of the variables was evaluated
by the tests of Shapiro-Wilk, Kolmogorov & Smirnov, and
Levene. Normally distributed variables were reported as
mean ± standard deviations. Diﬀerences among groups
in baseline characteristics were evaluated using one-way
analysis of variance. When diﬀerences were detected, a
Tukey’s post hoc test was performed to determine pairwise
diﬀerences. Primary analyses included two-way repeated
measures analysis of variance to test for interaction and
for main eﬀects of soy isoﬂavone and resistance training.
All analyses were performed with no intention-to-treat.
Comparison of daidzein and genistein levels between ISO
and PL groups was carried out by an independent t-test.
Exact P values were obtained from the tests employed.
Statisticaltestsweretwotailedandsigniﬁcancewassetat5%.
3. Results
Of the 80 postmenopausal women who were randomized, 71
completed this 9-month trial in the following four groups:
RT + ISO (n = 15), No RT + ISO (n = 2 0 ) ,R T+P( n =
18), and No RT + P (n = 18). As expected, dropout rates
were higher in the RT groups (n = 7) than in the No RT
groups (n = 2) because of the time commitment. However,
no diﬀerences in dropout rates were observed between ISO
(n = 5) and Placebo (n = 4) groups.
At baseline, weight and BMI were lowers in the RT + P
group compared with No RT + ISO and No RT + P,
respectively, but not signiﬁcantly diﬀerent in other variables.
Subject characteristics, fat, and muscle mass (MM)
showed no signiﬁcant diﬀerences among groups (Table 1).
No signiﬁcant diﬀerences were observed in energy or
macronutrient intake per kg body mass (P>. 05). Energy/kg
intakeswere24±6, 25±7, 23±6,and 22±6kcal/kg per day,
carbohydrate/kg intakes were 2.5 ± 0.6, 2.2 ± 1.4, 2.2 ± 1.0,
and 2.4 ± 0.6g/kg/day, protein/kg intakes were 1.0 ±
0.4, 1.1 ± 0.5, 1.1 ± 0.6, and 1.1 ± 0.5g/kg/day,
andfat/kg intakes were 0.82 ±0.32, 0.84 ±0.29, 0.82 ±0,34,
and 0.83±0.28g/kg/day for RT+ISO, RT+P, No RT+ISO,
and No RT+P, respectively.
Only groups with RT (RT + ISO and RT + P) increased
thestrength.However,nointeractionbetweenisoﬂavoneand
resistance training on muscle strength changes was found
(Figure 1). There was a main eﬀect of resistance training for
muscle strength such that muscle ﬁtness during the 9-month
intervention was improved in the RT groups (35.2%) and
reduced in the No RT groups (−1.1%). No main eﬀect of soy
isoﬂavone for muscle strength (ISO versus Placebo groups)
was observed.
Over body composition (fat and muscle mass), there was
am a i ne ﬀect of resistance training (Table 2) such that MM
improved in the RT groups (1.4% total-MM and 3.6% limb-
MM), and decreased in the No RT groups (−1.8% total-MM
and −0.7% limb-MM) during the 9-month intervention.4 Obstetrics and Gynecology International
Table 1: Baseline clinical characteristics of 71 postmenopausal women (mean ± SD).
Variables RT + ISO RT + P No RT + ISO No RT + P P value
∗
(n = 15) (n = 18) (n = 20) (n = 18)
Age (years) 55.7 ±7.05 6 .6 ±8.85 6 .0 ±5.85 5 .3 ±8.0. 9 9
Postmenopause (years) 7.7 ±5.38 .7 ±6.16 .5 ± 4.97 .7 ±6.2. 6 4
FSH (mUI/mL) 74.0 ±27.77 1 .8 ±24.36 3 .0 ± 21.16 3 .3 ±21.3. 1 5
E2 (pg/mL) 23.1 ±4.82 1 .7 ±4.32 2 .5 ±4.82 3 .3 ±5.8. 5 9
Weight (kg) 73.2 ±15.16 2 .8 ±9.8(a) 75.0 ±12.9(a) 73.7 ±12.6. 0 3
Height (cm) 154.9 ± 7.0 154.7 ±5.6 158.1 ±5.8 155.6 ±5.2. 2 7
WC (cm) 95.7 ±10.18 7 .3 ±7.79 4 .1 ± 12.39 5 .1 ±11.9. 0 9
BMI (kg/m2)3 0 .3 ±4.72 6 .0 ±3.0(a) 30.1 ±4.73 0 .4 ±5.3(a) .03
MM (kg) 34.0 ±6.23 0 .3 ±4.13 4 .0 ±4.23 3 .6 ±4.0. 0 8
MM-Limbs (kg) 13.6 ±2.81 2 .0 ±1.91 3 .7 ±2.01 3 .6 ±2.0. 0 8
MM (%) 52.2 ±4.55 4 .3 ±4.25 1 .2 ±6.25 1 .0 ±5.1. 2 0
Trunk fat mass (kg) 14.3 ±4.41 2 .3 ±3.21 5 .8 ±5.41 4 .8 ±4.4. 1 1
Body fat (%) 46.2 ±4.94 3 .0 ±4.44 6 .8 ±6.74 6 .5 ±5.7. 1 2
Strength muscle (kg) 30.7 ±9.23 1 .3 ±6.83 3 .0 ± 10.23 2 .7 ±7.9. 1 5
FSH: follicle-stimulating hormone; E2: estradiol; WC: waist circumference; BMI: body mass index; MM: muscle mass; SD: standard deviations; ISO:
isoﬂavone; PL: placebo; RT: resistance training.












RT + ISO RT + P No RT + ISO No RT + P
Figure 1: Percent changes in muscle strength (leg extension) from
baselineto9monthsinresponsetoexerciseandisoﬂavone.ANOVA
(p): ISO × Time = 0.82. RT × Time = 0.02. Interaction = 0.86.
Exercising attenuated fat trunk gains (RT = 6.1% versus
No RT = 11.2%, P<. 05) and % body fat (RT = 0.2%
versus No RT = 2.1%, P<. 05). No main eﬀect of soy
(ISO versus Placebo groups) was observed (Table 2). There
were no signiﬁcant interactions of isoﬂavone associated with
resistance training on changes in fat mass or MM (Table 2).
Table 3showsthatdaidzeinandgenisteinplasmaconcen-
trations signiﬁcantly diﬀered among groups after 9 months
of intervention (P<. 001). In the subjects given standardized
soy extract, the detectable levels of both isoﬂavones were
signiﬁcantly higher than in the placebo group.
Seven of the 35 soy group subjects (20%) and four of
the 36 placebo group subjects (11.1%) reported adverse
experiences, most frequently in the gastrointestinal system.
No serious adverse event related to isoﬂavone treatment was
reported.
4. Discussion
The ﬁndings of this investigation assessing the isolated and
combined eﬀects of exercise and soy isoﬂavone for 9 months
in postmenopausal women were the following: (1) resistance
training favorably changed body composition increasing
muscle mass and strength, and attenuating % body fat gains,
(2) standardized soy extract (100mg/day of isoﬂavone) did
not change body composition (fat and muscle mass), and (3)
there were no apparent additive or synergistic eﬀects of soy
isoﬂavone and resistance training on body composition.
Important changes in the body composition of a female
occur around the menopausal period. These changes include
a decrease in bone, strength, and muscle mass and an
increase in fat mass that can be managed by exercise,
nutrition, and estrogen replacement, or by their combined
intervention [1, 7, 8, 22]. In this study, the subjects engaged
in resistance training gained strength and muscle mass
(MM), whereas those in the nonexercising groups exhibited
loss. Progressive resistance exercise or strength training
is considered a promising intervention for reversing the
loss of muscle function and the deterioration of muscle
structure that is associate with aging [7, 23]. The American
College of Sports Medicine currently recommends strength
or resistance training as key components of an overall ﬁtness
program [20]. There is general consensus that physical
exercise is a powerful intervention to obtain long-term
beneﬁts in muscle function, to reduce the frequency of
falls, and to maintain independence and a high quality
of life in older persons [3, 24]. Although the skeletal
and muscular systems are structurally interdependent, both
adapt to mechanical loading; however, the nature of their
relationshipisstillunknown.Thefactorsnecessarilyrequired
to elicit changes to these systems have been studied. Fat-freeObstetrics and Gynecology International 5
Table 2: Eﬀects of soy (ISO) and/or exercise (RT) on body composition (fat and muscle mass) in the study groups at baseline and at 9
months (mean ± SD).
Variables RT + ISO RT + P No RT + ISO No RT + P
(n = 15) (n = 18) (n = 20) (n = 18)
MM (Kg)
Baseline 34.0 ±6.23 0 .3 ±4.13 4 .0 ±4.23 3 .6 ±4.0
After 9 months 34.6 ±6.13 0 .6 ±3.73 3 .2 ±3.83 3 .1 ±4.1
ANOVA (p)
ISO × Time 0.61
RT × Time <0.01
Interaction 0.19
Limb-MM (kg)
Baseline 13.6 ±2.81 2 .0 ±1.91 3 .7 ±2.01 3 .6 ±2.0
After 9 months 14.2 ±2.91 2 .3 ±1.91 3 .7 ±2.21 3 .4 ±1.9
ANOVA (p)
ISO × Time 0.05
RT × Time <0.00
Interaction 0.67
MM (%)
Baseline 52.2 ±4.55 4 .3 ±4.25 1 .2 ±6.25 1 .0 ±5.1
After 9 months 52.4 ±4.85 4 .3 ±5.05 0 .0 ±6.05 0 .3 ±5.6
ANOVA (p)
ISO × Time 0.79
RT × Time 0.04
Interaction 0.48
Trunk fat mass (kg)
Baseline 14.3 ±4.41 2 .3 ±3.21 5 .8 ±5.41 4 .8 ±4.4
After 9 months 15.4 ±5.31 2 .9 ±3.71 7 .2 ±6.11 6 .7 ±5.6
ANOVA (p)
ISO × Time 0.96
RT × Time 0.04
Interaction 0.28
Whole-body fat mass (kg)
Baseline 31.1 ±10.32 4 .8 ±6.23 2 .2 ±9.73 1 .3 ±8.8
After 9 months 31.8 ±10.02 5 .6 ±7.43 3 .8 ±10.73 2 .8 ±9.2
ANOVA (p)
ISO × Time 0.94
RT × Time 0.12
Interaction 0.85
Body fat (%)
Baseline 46.2 ±4.94 3 .0 ±4.44 6 .8 ±6.74 6 .5 ±5.7
After 9 months 45.6 ±5.14 3 .8 ±5.84 8 .4 ±6.84 8 .0 ±6.1
ANOVA (p)
ISO × Time 0.25
RT × Time 0.02
Interaction 0.20
has been suggested as a stronger determinant of bone mass
with aging than either total mass or fat mass, although fat
mass may also be an independent determinant [25].
In women, muscle mass and strength decline during
perimenopause and this phenomenon seems to be estrogen
dependent[1,7].Theoretically,estrogenhasadirectanabolic
action on the skeletal muscle that contains estrogenic
receptors [14]. Aubertin-Leheudre et al. [18]i n v e s t i g a t e d
whether six months of isoﬂavone supplementation (70mg
of isoﬂavones/day) would increase fat-free mass and muscle6 Obstetrics and Gynecology International
Table 3: Daidzein and genistein plasma levels at 9 months of
intervention (mean ± SD).
Parameter Isoﬂavone Placebo P-values
∗
(n = 35) (n = 36)
Daidzein (μmol/dL) 220.4 ±53.5 125.4 ±27.9 <.0001
Genistein (μmol/dL) 144.3 ±50.56 8 .1 ±19.5 <.0001
∗Signiﬁcant diﬀerence among groups (P<. 05) (independent t-test).
mass index in obese-sarcopenic postmenopausal women.
After 24 weeks, they found that limb and leg fat-free mass
and muscle mass index (MMI = appendicularFFM/height
2)
signiﬁcantly increased in the isoﬂavone group, but not in
the placebo group. Although the data suggest that isoﬂavone
improves muscle mass, we did not observe association in
this study and other ones [10]. A possible explanation
would be that these nonsteroidal compounds are weakly
bound to estrogenic receptors (<1% of estradiol binding
aﬃnity) [13]. Besides, soy isoﬂavones preferentially bind to
β-estrogen receptors that are found in the central nervous
system,bones,vascularwalls,andtheurogenitaltract.Unlike
estrogens, isoﬂavones have little aﬃnity with α-estrogen
receptors [26] ,w h i c ha r ef o u n di nl a r g e ra m o u n ti nt h e
muscle [14]. Additionally, the form of isoﬂavones may
impact the appropriateness of the dose used in present
study. Izumi et al. [27] showed that the isoﬂavone aglycones
were absorbed faster and in greater amounts than their
glycosides in humans. Nevertheless, these ﬁndings have not
been universal [28, 29].
Though the weight and IMC have been smaller in
RT + P, compared with other groups, the other variables
of the corporal composition (muscle mass and body fat)
and strength muscle did not show signiﬁcant diﬀerences
(Table 1). The postmenopausal women participating in our
study were overweight, with an elevate rate of body fat
and android fat distribution. Menopausal transition has
been associated with a preferential increase in intraab-
dominal fat that is independent of age and total body fat
mass [1], supporting the participation of sex hormones
in body fat distribution. In this study, no reduction in
body fat was observed after the nine-month interven-
tion. Nonetheless, two weekly sessions of resistance train-
ing associated with lower trunk fat gains and lower %
body fat gains. Resistance training has been shown to
increase resting and total energy expenditure, and to induce
decreases in total and abdominal fat [10, 11]. Hunter
et al. [11] demonstrated that resistance training reduces
the percentage of subcutaneous and intraabdominal fat in
women, On the other hand, studies conducted in post-
menopausal women showed no reduction in fat tissue [30,
31].
Little is known about the eﬀects of isoﬂavones on
body composition or fat and lean mass distribution in
postmenopausal women. The rationale for studying the
eﬀectofsoyproteinonbodyfatdistributionisthatisoﬂavone
may bind to estrogenic receptors of fat and lean tissues
promoting gynoid fat deposition [19]. Goodman-Gruen and
Kritz-Silverstein [32] investigated the association between
dietary isoﬂavone intake and body composition in 208
participants to the Soy Health Eﬀects Study (aged 45–74
years). They observed a signiﬁcant inverse relation between
soy consumption and body mass index, abdominal circum-
ference and fat mass, as well as no correlation with lean
mass, suggesting that an isoﬂavone-rich diet is associated
with reduced body fat and may play a role in the prevention
of obesity-related chronic diseases.
In agreement with our ﬁndings, Moeller et al. [19]
assessed body composition and physical activity in 69 peri-
menopausal women and found that 40g of soy protein/day
did not prevent abdominal fat deposition, but physical
activity positively correlated with the regional distribution
of fat and muscle mass. In 2007, Maesta et al. [10] assessed
the eﬀect of soy protein and progressive resistance training
onbody composition inpostmenopausal womenconcluding
that there were no additive eﬀects of soy and exercise. Soy
protein supplementation did not inﬂuence body composi-
tion indicators. Indeed, the increase in muscle mass and
reduction in abdominal fat were correlated with resistance
training.
The ﬁndings herein reported should be interpreted with
caution as this study presented some limitations. First,
the sample size was relatively small due to the inclusion
criteria and nature of the intervention (resistance training)
used. Second, although the participants were oriented, the
ingestion of food with isoﬂavone was not controlled. This
might explain high daidzein and genistein plasma levels
the in the placebo group, interfering in diﬀerence between
perceptual changes. Finally, the dropout rate ranged from
2.5% in the No RT groups to 20% in the RT groups.
These rates are high, but still comparable with those
observed in other trials involving exercising [33]. As a
matter of fact, the most frequently reported reason for
dropping-out and poor compliance was lack of interest to
continue with the resistance-training protocol. This study
was designed to assess the eﬀect of resistance training
combined with soy isoﬂavone on body composition in the
women who completed the program, and not to determine
the eﬀectiveness of such intervention in a public health or
community setting. Thus, the subjects who dropped out or
did not meet compliance requirements were not retested
and no intention-to-treat analysis was performed post
hoc.
In conclusion, our results indicate that standardized
soy extract (100mg/day of isoﬂavone) did not change
body composition (fat and muscle mass) and that soy
isoﬂavone and resistance training had no apparent additive
or synergistic eﬀects. Resistance training was found to be a
safeandeﬀectiveinterventionforreversingthelossofmuscle
function by increasing muscle mass and strength and to
attenuate fat trunk gains and % body fat in postmenopausal
women.
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